Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Tue Apr 21, 6:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), Urogen Pharma (URGN) and Johnson & Johnson (JNJ) with bullish sentiments.

Claim 30% Off TipRanks

Revolution Medicines (RVMD)

In a report released today, Laura Prendergast from Stifel Nicolaus reiterated a Buy rating on Revolution Medicines, with a price target of $215.00. The company’s shares closed last Friday at $148.63.

According to TipRanks.com, Prendergast is a 5-star analyst with an average return of 59.8% and a 63.4% success rate. Prendergast covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Black Diamond Therapeutics, and Olema Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $163.88 average price target, implying a 9.6% upside from current levels. In a report issued on April 6, LifeSci Capital also maintained a Buy rating on the stock with a $144.00 price target.

See the top stocks recommended by analysts >>

Urogen Pharma (URGN)

Piper Sandler analyst Kelsey Goodwin maintained a Buy rating on Urogen Pharma today and set a price target of $40.00. The company’s shares closed last Friday at $22.54.

According to TipRanks.com, Goodwin is a 5-star analyst with an average return of 66.8% and a 76.6% success rate. Goodwin covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Black Diamond Therapeutics, and Janux Therapeutics Inc. ;'>

Urogen Pharma has an analyst consensus of Strong Buy, with a price target consensus of $37.40, a 69.8% upside from current levels. In a report issued on April 9, Jefferies also initiated coverage with a Buy rating on the stock with a $40.00 price target.

Johnson & Johnson (JNJ)

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Johnson & Johnson, with a price target of $266.00. The company’s shares closed last Friday at $234.18.

According to TipRanks.com, Divan is a 5-star analyst with an average return of 11.7% and a 57.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Eledon Pharmaceuticals, and Travere Therapeutics. ;'>

Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $263.29, implying a 12.3% upside from current levels. In a report issued on April 7, Citi also maintained a Buy rating on the stock with a $285.00 price target.

Read More on RVMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).